Cervical cancer is primarily caused by persistent infection with certain types of human papillomavirus (HPV). Routine cervical screenings, such as Pap tests and HPV tests, can detect precancerous changes early on, enabling timely intervention and treatment.
Cervical cancer is a type of cancer that develops in the cells of the cervix, the lower part of the uterus that connects to the vagina. It is the fourth most common cancer in women worldwide and accounts for approximately 7% of all cancer deaths in women.
According to the American Cancer Society, an estimated 14,480 new cases of cervical cancer will be diagnosed in the United States in 2023, and approximately 4,290 women will die from the disease. The incidence of cervical cancer has declined significantly in recent decades due to increased awareness and screening for precancerous cells, but it remains a significant health concern, particularly in low-income countries.
The prognosis for cervical cancer varies depending on the stage of the cancer at diagnosis. The five-year survival rate for women with localized cervical cancer is approximately 91%, but this drops to 57% for women with regional spread and 17% for women with distant metastases.
Cervical cancer is divided into 5 stages based on the size of the tumour and how far it has spread. Stage 0 refers to precancerous cells, while Stage I refers to cancer that is confined to the cervix. Stage II indicates that the cancer has spread beyond the cervix but not to the pelvic wall, while Stage III indicates that the cancer has spread to the pelvic wall and/or lower vagina. Stage IV refers to cancer that has spread to other parts of the body, such as the bladder or rectum.
Our Dendritic Cell Therapy is a natural immunotherapy that can be used to help fight cervical cancer. Dendritic cells are immune cells that play a key role in activating the immune system to attack cancer cells. At Immucura, we take a patient’s dendritic cells from their blood and then expose them to pieces of cancer cells. This process activates the dendritic cells, which are then reinjected into the patient’s body. Once in the body, these activated dendritic cells can help stimulate the patient’s immune system to recognize and attack cancer cells.
Several clinical trials have investigated the use of Dendritic Cell Therapy for the treatment of cervical cancer. Several studies have shown promising results in terms of improving survival rates and reducing the risk of recurrence.
Cervical cancer is a serious health concern for women. Fortunately, Immucura offers a highly effective Dendritic Cell Therapy that can be combined with any other type of cancer therapy to provide maximum benefit.
Thanks to the testimony of many of Immucura’s patients, little by little this therapy is becoming better known among cancer patients, as for example the testimony of Daniela: “We thank you for all your support during these trying times. We are impressed and reassured of your method, and I will personally spread the word. So many lives could be saved! “I did not have any side effects at all, and now I feel much better now, I am alert physically. The team is fantastic, everybody is there to help with everything required. I would suggest it to anybody, try immunotherapy, it worked for me. I am still alive after three years. “
To read more patients’ testimonial, visit this section: Success Stories
© 2025 Immucura. All Rights Reserved
